CILP Polyclonal Antibody, PE-Cy7 Conjugated
Product Specifications
Background
Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage.
Synonyms
CILP-1; HsT18872; Cartilage intermediate layer protein 1; Cartilage intermediate-layer protein; CILP; UNQ602/PRO1188
Gene ID
8483
Swiss Prot
O75339
Cellular Locus
Cytoplasm
Host
Rabbit
Cross Reactivity
Human, Mouse, Rat
Immunogen
1051-1184/1184
Target
CILP
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy7
Source
KLH conjugated synthetic peptide derived from human CILP
Applications
WB, FCM
Purification
Purified by Protein A.
Excitation Emission
488nm/780nm
Concentration
1µg/µl
Dilution
WB (1:300-5000), FCM (1:20-100)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Specificity
The immunogen falls within the Cartilage intermediate layer protein 1 C2 region.
Gene ID URL
8483
Predicted Cross Reactivity
Cow, Sheep, Horse
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15086345 1 Vial
Lentiviral human PGLYRP3 shRNA (UAS) - Lentiviral human PGLYRP3 shRNA (UAS) (25)
Ask
View Details 
